Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma

A conserved dendritic-cell regulatory program limits antitumour immunity

(2020) Barbara Maier et al.   NATURE

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

(2019) Caroline Robert et al.   LANCET ONCOLOGY

ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer

(2019) Guru Sonpavde et al.   Future Oncology

Abstract CT004: Front-line therapy of DIPG using the IDO pathway inhibitor indoximod in combination with radiation and chemotherapy

(2018) Theodore S. Johnson et al.   CANCER RESEARCH

Abstract 3753: Indoximod modulates AhR-driven transcription of genes that control immune function

(2018) Erik L. Brincks et al.   CANCER RESEARCH

Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study.

(2018) Georgina V. Long et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 2 trial of the IDO pathway inhibitor indoximod plus gemcitabine / nab-paclitaxel for the treatment of patients with metastatic pancreas cancer.

(2018) Nathan Bahary et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond

(2018) Alexander J. Muller et al.   Seminars in Immunopathology

A phase I study of indoximod in patients with advanced malignancies

(2016) Hatem H. Soliman et al.   Oncotarget

514 Results of Phase 1b trial of the Indoleamine 2,3-dioxygenase (IDO) Pathway Inhibitor Indoximod plus Ipilimumab for the treatment of unresectable stage III or IV melanoma

(2015) Y. Zakharia et al.   EUROPEAN JOURNAL OF CANCER

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner

(2015) Rikke B. Holmgaard et al.   Cell Reports

Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors

(2014) D. A. Wainwright et al.   CLINICAL CANCER RESEARCH

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment

(2014) Stefani Spranger et al.   Journal for ImmunoTherapy of Cancer

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

(2013) Rikke B. Holmgaard et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells

(2013) S. Spranger et al.   Science Translational Medicine

Amino acid catabolism: a pivotal regulator of innate and adaptive immunity

(2012) Tracy L. McGaha et al.   IMMUNOLOGICAL REVIEWS

Reprogrammed Foxp3+ Regulatory T Cells Provide Essential Help to Support Cross-presentation and CD8+ T Cell Priming in Naive Mice

(2010) Madhav D. Sharma et al.   IMMUNITY

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma

(2010) Evan M. Hersh et al.   INVESTIGATIONAL NEW DRUGS

Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes

(2009) M. D. Sharma et al.   BLOOD

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER